Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (45035)	10/12/1999 2:05:00 PM
From: Tech Master	Respond to of 122087

What do you think about this company? For the record- I'm long here. Tuesday October 12, 9:59 am Eastern Time Company Press Release Columbia/HCA Member Hospital to Begin Phase I Clinical Trials of Celsion's Cancer Treatment System for Ablation of Breast Tumors Breast Cancer Treatment System Installed at a Columbia/HCA Member Hospital in Florida; Second Installation Expected Shortly at UCLA COLUMBIA, Md.--(BW HealthWire)--Oct. 12, 1999-- Celsion Corp. (OTC BB:CELN - news), in conjunction with Columbia/HCA Healthcare Corp., today announced that the Company installed its breast cancer treatment system at a Columbia/HCA member hospital in West Palm Beach, Florida, which is now recruiting patients for Phase I clinical studies of Celsion's system. Celsion reported that Phase I clinical studies of its breast cancer treatment will also begin shortly at Harbor UCLA Medical Center in California to expedite patient accrual and accelerate the trials. ''We are very optimistic that Celsion's breast cancer system will significantly improve treatment results and ultimately lead to a kinder and gentler approach to breast cancer ablation,'' commented Dr. Robert Gardner, chief of the Center for Breast Care at Columbia Hospital Breast Center and co-investigator of the Phase I clinical trials. ''I am pleased to say that Columbia Hospital Breast Center is now recruiting patients for these clinical evaluations,'' continued Dr. Gardner, ''and encourage women suffering from the disease to contact our facility regarding possible participation in what we hope will be a dramatic breakthrough in breast cancer treatment. I am also excited to say that we expect our patient recruitment process to run quite smoothly since October is national breast cancer awareness month.'' The Phase I clinical trials will evaluate the safety of Celsion's focused heat treatment system, which is designed to destroy cancerous tumors and viable cancer cells using heat alone. The device is a thermotherapy delivery system that is hoped to provide a non-surgical, minimally invasive treatment, which is non-toxic and side effect free. The Company's treatment system incorporates the proprietary Adaptive Phased Array (APA) focusing technology that was developed by the Massachusetts Institute of Technology (MIT) and is exclusively licensed worldwide to Celsion. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia using focused heat delivered by patented microwave technology. Clinical trials and further development of the Company's treatment systems are being conducted by leading institutions such as Columbia Hospital (a Columbia/HCA Healthcare member), Duke University, Harbor UCLA Medical Center, Massachusetts Institute of Technology and Montefiore Medical Center. Forward-looking statements in this release are made pursuant to the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.